Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Matthew Z Guo"'
Autor:
Catalina Pereira, Gerardo A Arroyo-Martinez, Matthew Z Guo, Michael S Downey, Emma R Kelly, Kathryn J Grive, Shantha K Mahadevaiah, Jennie R Sims, Vitor M Faca, Charlton Tsai, Carl J Schiltz, Niek Wit, Heinz Jacobs, Nathan L Clark, Raimundo Freire, James Turner, Amy M Lyndaker, Miguel A Brieno-Enriquez, Paula E Cohen, Marcus B Smolka, Robert S Weiss
Publikováno v:
eLife, Vol 11 (2022)
DNA damage response mechanisms have meiotic roles that ensure successful gamete formation. While completion of meiotic double-strand break (DSB) repair requires the canonical RAD9A-RAD1-HUS1 (9A-1-1) complex, mammalian meiocytes also express RAD9A an
Externí odkaz:
https://doaj.org/article/57deb83a4c11495681d45121899c60e3
Autor:
Tia Cheunkarndee, BA, Matthew Z. Guo, BA, Stefanie Houseknecht, PharmD, Josephine L. Feliciano, MD, Christine L. Hann, MD, PhD, Vincent K. Lam, MD, Benjamin P. Levy, MD, Joseph C. Murray, MD, PhD, Julie R. Brahmer, MD, Patrick M. Forde, MBBCh, Kristen A. Marrone, MD, Susan C. Scott, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 6, Pp 100686- (2024)
Introduction: Up to 20% of EGFR-mutated NSCLC cases harbor uncommon EGFR mutations, including atypical exon 19 and compound mutations. Relatively little is known about the efficacy of osimertinib in these cases. Methods: Patients treated with first-l
Externí odkaz:
https://doaj.org/article/05807ac9bd2f42b798126635e1f75ec4
Autor:
Tia Cheunkarndee, BA, Matthew Z. Guo, BA, Jacqueline E. Birkness-Gartman, MD, Kiyoko Oshima, MD, Cheng Ting Lin, MD, Kristen A. Marrone, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100448- (2023)
As novel therapeutic regimens continue to lead to increased survival of patients with lung cancer, it is imperative to remain mindful of the accompanying increase in the incidence of new primary malignancies. Although the most common secondary malign
Externí odkaz:
https://doaj.org/article/a3e4cd704f17417ebcbd38eb8edfc302
Publikováno v:
Future Oncology.
Adagrasib is a recently US FDA-approved novel KRASG12C targeted therapy with clinical efficacy in patients with advanced, pretreated KRASG12C-mutated non-small-cell lung cancer. KRYSTAL-I reported an objective response rate of 42.9% with median durat
Publikováno v:
Journal of general internal medicine, vol 37, iss 9
Online education due to the COVID-19 pandemic caused many medical schools to increasingly employ asynchronous and virtual learning that favored student independence and flexibility. At the same time, the COVID-19 pandemic highlighted existing shortco
Publikováno v:
The Cancer Journal. 27:476-481
Publikováno v:
OncoTargets and therapy
MET dysregulation promoting tumorigenesis in non-small cell lung cancer (NSCLC) is associated with worse outcomes following chemotherapy as compared to non-driver mutated NSCLC and occurs either through mutations causing MET exon 14 skipping (METex14
Autor:
Matthew Z. Guo, Joseph C. Murray, Paola Ghanem, K Ranh Voong, Russell K. Hales, David Ettinger, Vincent K. Lam, Christine L. Hann, Patrick M. Forde, Julie R. Brahmer, Benjamin P. Levy, Josephine L. Feliciano, Kristen A. Marrone
Publikováno v:
Clinical lung cancer. 23(7)
Consolidation durvalumab immunotherapy following definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC) improves overall survival. As therapeutic options for patients with KRAS-driven disease evolve, more unders
Autor:
Catalina Pereira, Gerardo A Arroyo-Martinez, Matthew Z Guo, Michael S Downey, Emma R Kelly, Kathryn J Grive, Shantha K Mahadevaiah, Jennie R Sims, Vitor M Faca, Charlton Tsai, Carl J Schiltz, Niek Wit, Heinz Jacobs, Nathan L Clark, Raimundo Freire, James Turner, Amy M Lyndaker, Miguel A Brieno-Enriquez, Paula E Cohen, Marcus B Smolka, Robert S Weiss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96989669e5391ebd7aac62be78017e04
https://doi.org/10.7554/elife.68677.sa2
https://doi.org/10.7554/elife.68677.sa2
Autor:
Anabella Maria D Galang, Timothy M. Pierpont, Robert S. Weiss, Amanda R Loehr, Andrew D. Miller, Irma Fernandez, Eric Gelsleichter, Elizabeth S. Moore, Matthew Z Guo
Publikováno v:
Cancers
Cancers, Vol 13, Iss 2045, p 2045 (2021)
Volume 13
Issue 9
Cancers, Vol 13, Iss 2045, p 2045 (2021)
Volume 13
Issue 9
Simple Summary Testicular germ cell tumors (TGCTs) are the most common solid malignancy in young men. Fortunately, these tumors are highly curable with conventional genotoxic chemotherapy. However, because these chemotherapeutics have significant sho